Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119–1123.
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903.
Keogh A, Macdonald P, Williams T, et al. Tracleer® (bosentan) for the treatment of pulmonary arterial hypertension: the six month quality of life data. J Heart Lung Transplant 2004; 23: S54 (abstr 36).
Galie N, Hinderliter AL, Torbicki A. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380–1386.
McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 2: 244–249.
Wagenvoort CA, Wagenvoort N. Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv Cardiol 1974; 11: 123–130.
Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the haemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15: 100–105.
Simonneau G, Barst RJ, Galie N, et al. Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804.
McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477–1482.
Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858–1865.
Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 2004; 94: 261–263.
Benza RL, Rayburn BK, Tallaj JA, et al. The safety and efficacy of bosentan in pulmonary hypertension due to congenital heart disease. J Heart Lung Transplant 2003; 22: S152 (abstr 242).
Gatzoulis M, Rogers P, Li W, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol 2005; 98: 147–51.
Sitbon O, Beghetti M, Petit J, et al. The endothelin receptor antagonist bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur Heart J 2004; 25: S22 (abstr 219).
Bowyer JJ, Busst CM, Denison DM, Shinebourne EA. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 1986; 55: 385–390.
Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164: 1682–1687.
Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247–254.
Rosenzweig EB, Barst RJ. Eisenmenger's syndrome: current management. Prog Cardiovasc Dis 2002; 45: 129–138.
Kapoor A, Sheppard R, Panyon J, Mathier MA, MacGowan GA, Murali S. Clinical outcome comparison in pulmonary artery hypertension patients treated with Epoprostenol and Bosentan. Circulation 2003; 108: IV-11 (abstr 52).
Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353–359.
Reichenberger F, Howard L, Parameshwar J, Morrell NW, Pepke-Zaba J. Nebulised iloprost in pulmonary arterial hypertension due to Eisenmengers syndrome. J Heart Lung Transplant 2003; 22: S153 (abstr 244).
Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066–2069.
Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 2004; 25: 431–436.
Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149–1153.
Rosenthal E. Circulation. 2004; 109: e197.
Dharmadhikari A, Airoldi F, Tzifos V, Sheiban I, Pathak L, Bansal N. Sildenafil in the treatment of atrial septal defect with moderate to severe pulmonary arterial hypertension. Eur Heart J 2004; 25: S10 (abstr 155).
Lacassie HJ, Germain AM, Valdes G, Fernandez MS, Allamand F, Lopez H. Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet Gynecol 2004; 103: 1118–1120.
Lewis GD, Bloch KD, Semigran MJ. Pulmonary thromboembolism superimposed on a congenital ventricular septal defect in a 50-year-old man: inhaled nitric oxide and sildenafil to the rescue. Cardiol Rev. 2004; 4: 188–190.
Ovadia B, Reinhartz O, Fitzgerald R, et al. Alterations in ET-1, not nitric oxide, in 1-week-old lambs with increased pulmonary blood flow. Am J Physiol Heart Circ Physiol 2003; 284: H480–H490.
Beghetti M, Black SM, Fineman JR. Endothelin-1 in congenital heart disease. Pediatr Res 2005; 57: R16–R20.
Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434–2440.
Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003; 73: 372–382.